Pfizer said its Covid-19 vaccine provided long-term protection in the latest study conducted with more than 2,000 children 12-15 years old.
Pfizer said its Covid-19 vaccine provided long-term protection in the latest study conducted with more than 2,000 children 12-15 years old.

The study also showed no serious safety concerns in those who were followed for at least 6 months after the second injection.

Out of the 2,228 participants in the trial, 30 of whom had symptoms of SARS-CoV-2 infection were in the placebo group. Pfizer says the results mean the vaccine is 100 percent effective in all genders, races, levels of obesity, and comorbidities.

The main concern about adverse events in this age group is the risk of myocarditis in male children with the vaccine. However, data show that myocarditis from the Covid-19 vaccine is rare and the benefits of vaccination outweigh the risks. Covid-19 disease also causes myocarditis at a higher rate and is more severe.

Pfizer CEO Albert Bourla said that the above data will help the company's Covid-19 vaccine to be fully licensed in the US and around the world.

"As the global health community is acting to drive increased immunization coverage around the world, these new data reinforce confidence in the safety and effectiveness of vaccines in adolescents." Bourla affirmed.
Axact

Global Trends

Giving you feeds on what's happening in America and the world at large. Be it in tech, politics, entertainment, health and sports..

Post A Comment:

0 comments:

Be Civil, No Spam!!!